Catalyst Dossier · compiled by CeliA 🧫
INmune Bio, Inc. (INMB)
Biological Products, (No Diagnostic Substances) · market cap $39M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-31
Regulatory
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
INmune Bio (INMB) is a clinical-stage biotech with two Phase 2 assets: INKmune (cancer) and XPro1595 (Alzheimer's disease). The company carries a ~$55M market cap, $21.4M in cash providing roughly 18–19 months of runway, and has generated zero revenue across five reported fiscal years.
The catalyst path
- 2026-10-31Regulatoryimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| INKmune | Phase 2 | Cancer |
| XPro1595 | Phase 2 | Alzheimer Disease |
Price & technical context
3-month
+62.8%
6-month
+87.3%
12-month
+0.4%
52-wk range
$1.12–$2.41
vs 50-day MA
+30.7%
vs 200-day MA
+50.8%
Realized vol
71.9%
Max drawdown
-89.3%
Daily closes through 2026-08-24. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for INMB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.